Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.
about
Optimizing antimicrobial therapy in critically ill patientsTreatment with echinocandins during continuous renal replacement therapyAntimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing Strategies.Antibiotic stewardship in the intensive care unit.Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.Effectiveness of pharmacist dosing adjustment for critically ill patients receiving continuous renal replacement therapy: a comparative study.β-lactam antibiotic concentrations during continuous renal replacement therapy.Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever.Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysisDaptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingRecommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapyPopulation pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltrationVancomycin continuous infusion versus intermittent infusion during continuous venovenous hemofiltration: slow and steady may win the racePharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis.Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider.Clinical update on linezolid in the treatment of Gram-positive bacterial infections.Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patientsEffect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrationsRole of linezolid in the treatment of complicated skin and soft tissue infections.PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration.Systemic tobramycin concentrations during selective decontamination of the digestive tract in intensive care unit patients on continuous venovenous hemofiltration.Need for quality improvement in renal systematic reviews.Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.Cefepime: a reappraisal in an era of increasing antimicrobial resistance.Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.Antimicrobial dosing in acute renal replacement.Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.New information about the polymyxin/colistin class of antibiotics.Antibiotic dosing in critically ill patients with acute kidney injury.Pharmacological considerations for the proper clinical use of aminoglycosides.Evaluation of antibiotic prescribing patterns in patients receiving sustained low-efficiency dialysis: opportunities for pharmacists.Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.
P2860
Q26999905-8693FAEA-FA64-496D-8E8E-4677399E816CQ27012864-E91E2E7A-EFD6-425B-931F-FBD9A3B446ABQ27313917-ED743413-F283-4EE5-8997-4A403B0784DBQ30408712-38DB9C1F-54FA-426A-AAC7-74C0ED066066Q33623078-F3FBBF75-BA68-42F4-A9BF-CB7CE8579413Q33654022-A64B209C-84C7-47E5-A474-FA3135CF89D7Q33734676-73BFA45A-7055-41C4-8C32-B331E35C077AQ33821438-6F7E1DC0-73DB-4F66-86C4-7B52C504E57AQ34252982-A5346DB9-6E37-4D9A-A3E4-E2DD95730656Q34290150-C8A1C65A-9DB8-4EBC-AC9A-E5682B9BF727Q34415375-BE18A48D-2D68-43FA-A3B6-3DD631FAAE60Q35026595-79BC9E1F-92F4-46FF-A417-85ADF276DED7Q35166807-8B0A91D6-78C2-48E2-BA0E-E56523653408Q35270646-6E1C8C78-2018-42FB-9AAB-53FD03A8BE42Q35541277-0954EC0C-FFF1-4FBE-AF78-5E44FEBD76C4Q35558292-48A87A19-4C7D-4826-BF1A-70D6B29D1C9BQ35598414-7005F0F2-DE1B-4B71-84B5-00103A898654Q35598435-65A2F19A-B424-4221-9A9C-88E034A7C956Q35614469-1908AB9A-EF0F-4F53-BF3D-CD22583A016DQ35827280-99EAE57C-08EE-49C3-9A46-4E9004C281CCQ35867327-2C42E812-BDBB-4AAA-A2B7-1BCB2E3A0E91Q36048276-60524279-9373-4DD3-BD5C-69E2E9B55C2BQ36070363-95235346-4B43-4B24-913A-428BBB90705BQ36083208-97CF65D8-822F-4D39-8B82-840A0DB1782FQ36087577-907E5613-C714-4A24-9044-EE0A501BAB5FQ36396233-EEA257E8-0C61-4F62-B668-B8D726461708Q36505478-8F8F1793-A6CF-4C27-B762-DD41DFC86041Q36507959-2133BCA6-C3D0-41B9-8E5F-2E2A2D0C1A21Q36570134-3B4F2DEA-211F-47E2-B303-8BF6772D5D09Q36736617-15FDC2AE-9439-4BDD-B6E4-BFC8C3CFC7B0Q36777821-0B01003F-5CEE-47D2-88C4-4B558573255BQ37079350-56EBE415-52FA-4672-B167-E4BB3E6F1C99Q37119964-6D254DDC-6DA4-4453-BFCF-B9FDA26CB3DDQ37252494-25BB344F-F0F7-4F45-85CC-E18738AF1DCCQ37461431-BA30F5F5-4D0C-445C-83F7-A61F529E9805Q37636150-21433C1A-B069-41E0-A371-9C6912210F23Q37846092-4D4A27A4-C2F9-45D0-8BC1-844E8963AFEEQ37956403-E2C14706-B9C8-4B72-8628-FE6FEEE4E2BFQ38072720-C6D0B48F-834C-4EC9-B49C-B38E76C4DA1DQ38090988-4CBC973D-2C96-42BB-B6E3-58F2519F7D9F
P2860
Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Antibiotic dosing in criticall ...... ous renal replacement therapy.
@ast
Antibiotic dosing in criticall ...... ous renal replacement therapy.
@en
type
label
Antibiotic dosing in criticall ...... ous renal replacement therapy.
@ast
Antibiotic dosing in criticall ...... ous renal replacement therapy.
@en
prefLabel
Antibiotic dosing in criticall ...... ous renal replacement therapy.
@ast
Antibiotic dosing in criticall ...... ous renal replacement therapy.
@en
P2093
P2860
P356
P1476
Antibiotic dosing in criticall ...... ous renal replacement therapy.
@en
P2093
D Matthew Shoemaker
John C Williamson
Robin L Trotman
William L Salzer
P2860
P304
P356
10.1086/444500
P407
P577
2005-09-12T00:00:00Z